Concepedia

Mark D. Erion

MD

Statistics

Publications

111

Citations

7.5K

H-Index

49

Active since

1982

Affiliations

Torrey Pines Institute For Molecular Studies(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Fate Therapeutics (United States)

Novartis (Switzerland)

Cornell University

Mark D. Erion is an author at Torrey Pines Institute For Molecular Studies specializing in pharmacology, enzyme inhibition, and medicinal chemistry.

Publications per year

1982–2022

111

Publications

111

Targeting a ceramide double bond improves insulin resistance and hepatic steatosis

Bhagirath Chaurasia, Trevor S. Tippetts, Rafael Mayoral et al. · Science · 2019 · 450 citations · Full text

Life Sciences, Biochemistry, Nutritional Sciences +17

Prodrugs of Phosphates and Phosphonates

Scott J. Hecker, Mark D. Erion · Journal of Medicinal Chemistry · 2008 · 412 citations

Pharmacy, Medicinal Chemistry, Pharmacology +8

Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy

Robert W. Myers, Hong-Ping Guan, Juliann Ehrhart et al. · Science · 2017 · 344 citations

Life Sciences, Biochemistry, Pharmacology +17

Targeting thyroid hormone receptor-β agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index

Mark D. Erion, Edward E. Cable, Bruce R. Ito et al. · Proceedings of the National Academy of Sciences · 2007 · 268 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Isolation of a Family of Organic Anion Transporters from Human Liver and Kidney

William Sun, Rong Wu, Paul D. van Poelje et al. · Biochemical and Biophysical Research Communications · 2001 · 219 citations

Engineering, Biochemistry, Nephrology +8

1–5 of 111